The Technical Analyst
Lipocine Inc [LPCN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Lipocine Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.26% $5.44
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.92 mill |
| EPS: | -3.14 |
| P/E: | -1.730 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 5.32 mill |
| Avg Daily Volume: | 0.0624 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.730 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.29x |
| Company: PE -1.730 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.898 (-83.50%) $-4.54 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.04 - 5.84 ( +/- 7.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-08 | Patel Mahesh V. | Buy | 4 893 | Common Stock |
| 2024-03-08 | Fogarty Krista | Buy | 991 | Common Stock |
| 2023-05-25 | Patel Mahesh V. | Buy | 8 706 | Common Stock |
| 2023-05-10 | Papapetropoulos Spyros | Buy | 30 000 | Stock Option (Right to Buy) |
| 2023-05-10 | Higuchi John W. | Buy | 30 000 | Common Stock (Right to Buy) |
| INSIDER POWER |
|---|
| 93.73 |
| Last 96 transactions |
| Buy: 4 769 643 | Sell: 1 163 369 |
Forecast:
16:00 - $5.43
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.43
Forecast 2: 16:00 - $5.43
Forecast 3: 16:00 - $5.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.44 (2.26% ) |
| Volume | 0.0212 mill |
| Avg. Vol. | 0.0624 mill |
| % of Avg. Vol | 33.99 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LPCN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 07:00:00 - Press Release
Lipocine Announces Positive Lpcn 2401 Clinical Results Showing Improved Body Composition In Participants With Obesity
Lpcn 2401 treatment resulted in statistically significant body composition improvement in men increased lean mass (lm) by 4.4% and decreased fat mass (fm) by 6.7% reduced android fat (af) by 4.1% and increased bone mineral content (bmc) by 2.8% well-tolerated, adverse events (aes) similar to placebo potential for use in combination with incretin mimetics (glp-1/gip agonists and/or post glp-1/gip agonist) or as a monotherapy post discontinuation conference call and webcast at 8.30 a.m. et today salt lake city , april 11, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company, today announced results from a phase 2 clinical trial (nct04134091) which includes lpcn 2401, an oral proprietary combination of anabolic androgen receptor agonist and Α-tocopherol, an antioxidant.
2024-03-28 08:00:00 - Press Release
Lipocine Announces Positive Week 52 Results From Lpcn 1148 Phase 2 Study In Patients With Cirrhosis
Met primary and hepatic encephalopathy (he) endpoints in phase 2 study increase in skeletal muscle index (smi) observed at week 24 was maintained through 52 weeks participants on placebo increased smi when switched to lpcn 1148 fewer overt hepatic encephalopathy (ohe) events and time to first recurrent ohe event was longer while on lpcn 1148 therapy lpcn 1148 was well-tolerated, with ae rates and severities similar to placebo. participants on lpcn 1148 were hospitalized for fewer days salt lake city , march 28, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company today announced positive topline results from a phase 2 clinical study of lpcn 1148.
2024-03-25 08:00:00 - Press Release
Lipocine Announces First Cohort Dosed In Pivotal Study Of Lpcn 1154
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 salt lake city , march 25, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (pk) study designed to support a new drug application (nda) for lpcn 1154. lpcn 1154, oral brexanolone, is being developed by lipocine for the treatment of postpartum depression (ppd).
2024-03-07 08:00:00 - Press Release
Lipocine Announces Financial Results For The Full Year Ended December 31, 2023
Salt lake city , march 7, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system ("cns") disorders, today announced financial results for the year ended december 31, 2023 and provided a corporate update. neuroactive steroids lipocine announced positive topline results from a pharmacokinetics ("pk") pilot bridge study of lpcn 1154 (oral brexanolone).
2024-03-06 08:00:00 - Press Release
Lipocine To Present At 36th Annual Roth Conference
Salt lake city , march 6, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders, today announced that dr. mahesh v. patel, president and chief executive officer, will participate in a fireside chat and meet with investors at the 36th annual roth conference, to take place in laguna niguel, ca, on march 18.
Latest News
2023-10-23 19:00:00 - PRNewsWire
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.
2023-07-27 08:40:05 - InvestorPlace
Why Is Lipocine (LPCN) Stock Up 32% Today?
Lipocine (NASDAQ: LPCN ) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. That trail covers the use of LPCN 1148 as a treatment for patients suffering from cirrhosis.
2023-06-07 08:00:00 - PRNewsWire
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver (EASL) Congress 2023, to take place in Vienna, Austria, June 21 – 24, 2023. A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148 Lead author and presenter: Dr...
2023-01-05 08:00:00 - PRNewsWire
Lipocine to Present at Biotech Showcase
Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Jan. 5, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary platform to develop differentiated products, today announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 9-11, 2023, in San Francisco, California.
2022-09-22 16:10:00 - PRNewsWire
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference
SALT LAKE CITY , Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of care, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29 in New York.
2022-03-29 19:34:26 - InvestorPlace
7 Undervalued Penny Stocks With Major Upside
Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. The post 7 Undervalued Penny Stocks With Major Upside appeared first on InvestorPlace.
2021-11-11 07:15:44 - Seeking Alpha
Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH Data
Lipocine has obtained positive results in a phase 2 study using its drug LPCN1144 for the treatment of patients with NASH.
2021-11-07 15:15:00 - PennyStocks
Penny Stocks to Buy Now? 5 Reddit Stocks To Watch This Week
2021-10-18 12:15:06 - Benzinga
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
Lipocine Inc (NASDAQ: LPCN) has entered into an exclusive licensing agreement with Antares Pharma Inc (NASDAQ: ATRS) to commercialize Tlando in the U.S. Tlando is an oral testosterone product for testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone.
2021-10-18 09:49:12 - PennyStocks
Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others
A jump in penny stock prices has retail traders cashing out on big gains. The post Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.